SynthesisDigestive diseases and sciences2020
Pyoderma Gangrenosum in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis.
Synthesis in Digestive diseases and sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed.
- Guselkumab as a Treatment Adjunct for Pyoderma Gangrenosum While Maintaining Clinical Remission of Ulcerative Colitis.ACG case reports journal · 2026Article
- Integrative Multi-Omics Analysis and Computational Modeling Identifying Shared Inflammatory Pathways and JAK Inhibitor Targets in PG and IBD.International journal of molecular sciences · 2026Article
- Cutaneous Manifestations and Dermatologic Adverse Events in IBD: A Clinical Update.Inflammatory bowel diseases · 2026Review
- International collaborative experiences in managing pyoderma gangrenosum in patients with inflammatory bowel disease.Therapeutic advances in gastroenterology · 2026Article
- Successful treatment of severe retroauricular pyoderma gangrenosum with upadacitinib in a patient with Crohn's disease and a history of cerebral venous sinus thrombosis.Therapeutic advances in gastroenterology · 2026Article
- Pyoderma Gangrenosum in a Patient with Crohn's Disease Treated with Adalimumab: A Case-Based Review and Systematic Review of the Current Literature.Clinics and practice · 2025Review
- Article
- Effects of immune cells in mediating the relationship between inflammatory bowel disease and pyoderma gangrenosum: a two-sample, two-step mendelian randomization study.Archives of dermatological research · 2025Article
- Pyoderma Gangrenosum and Inflammatory Bowel Disease: Recent Insights into Epidemiology, Pathogenesis, and Therapeutic Approaches.Journal of inflammation research · 2025Review
- Extraintestinal Manifestations in Inflammatory Bowel Disease: From Pathophysiology to Treatment.Biomedicines · 2024Review
- Successful Outcome Treating Pyoderma Gangrenosum and Pouchitis With Upadacitinib.ACG case reports journal · 2024Article
- Upadacitinib Plus Intensive Granulocyte and Monocyte Adsorptive Apheresis for Ulcerative Colitis Achieved Ulcer Healing for Pyoderma Gangrenosum.Journal of clinical medicine research · 2023Article
- Current insights on the roles of gut microbiota in inflammatory bowel disease-associated extra-intestinal manifestations: pathophysiology and therapeutic targets.Gut microbes · 2023Review
- Ulcerative Colitis Diagnosed through Evaluation of Underlying Diseases in a Pyoderma Gangrenosum Adolescent without Gastrointestinal Symptoms.Annals of dermatology · 2023Article
- Cutaneous manifestations of inflammatory bowel disease: basic characteristics, therapy, and potential pathophysiological associations.Frontiers in immunology · 2023Review
- A novel murine model of pyoderma gangrenosum reveals that inflammatory skin-gut crosstalk is mediated by IL-1β-primed neutrophils.Frontiers in immunology · 2023Article
- Cutaneous Manifestations of Inflammatory Bowel Disease: A Basic Overview.American journal of clinical dermatology · 2022Review
- A United States expert consensus to standardise definitions, follow-up, and treatment targets for extra-intestinal manifestations in inflammatory bowel disease.Alimentary pharmacology & therapeutics · 2022Article
- Essential updates 2020/2021: Colorectal diseases (benign)-Current topics in the surgical and medical treatment of benign colorectal diseases.Annals of gastroenterological surgery · 2022Review
- Atypical Forms of Pyoderma Gangrenosum in Inflammatory Bowel Disease: Report of Four Cases and Literature Review.International medical case reports journal · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPyoderma gangrenosum (PG) is an uncommon but severe extra-intestinal manifestation (EIM) of inflammatory bowel disease (IBD). The incidence and risk factors for PG are disputed.
aimsTo assess the incidence of PG and identify factors associated with PG in IBD patients.
methodsA search of electronic databases (Ovid and PubMed) was conducted between 1966 and 2019. Studies that calculated the incidence of PG in IBD patient cohorts were included. Patient demographics, IBD subtype, and EIM presence were recorded. A review of our institutional database of 1057 IBD patients was conducted. A multivariate regression model and meta-analysis were conducted to identify risk factors for PG. A random effects model was used to combine the data of included studies.
resultsFourteen studies were included in addition to 1057 IBD patients and 26 PG cases from the Louisville cohort. In total, there were 379 cases of PG in the cumulative cohort of 61,695 IBD patients. The PG incidence in individual studies ranged from 0.4 to 2.6%. In the institutional cohort, ocular EIMs and a permanent stoma were significant risk factors for PG. In the meta-analysis, PG was associated with female gender (RR = 1.328, 95% CI 1.161-1.520), Crohn's disease (RR = 1.193, 95% CI 1.001-1.422), erythema nodosum (RR = 9.281, 95% CI 6.081-14.164), and ocular EIM (RR = 4.55, 95% CI 3.04-6.81). There was study heterogeneity when assessing IBD subtype, ocular, and joint EIMs.
conclusionsThere are conflicting data on the incidence and risk factors for PG. This meta-analysis confirms an association between PG and female gender, Crohn's disease, erythema nodosum, and ocular EIM that have been described in smaller studies.
Indexed as
Identifiers
31925675What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.